对镥-前列腺特异性膜抗原治疗的显著反应因神经内分泌转化而受到影响。
An exceptional response to LuPSMA undermined by neuroendocrine transformation.
作者信息
Bilinski Pretoria, Webb Myles
机构信息
Oncology Department, Greenslopes Private Hospital, Newdegate Street, Greenslopes, Queensland, Australia.
Queensland X-ray PET/CT Centre, Lower Ground Level, Greenslopes Private Hospital, Newdegate Street, Greenslopes, Queensland, Australia.
出版信息
Urol Case Rep. 2020 Oct 24;34:101467. doi: 10.1016/j.eucr.2020.101467. eCollection 2021 Jan.
Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation do not express PSMA and are not affected by this treatment. This case highlights an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver.
在接受广泛全身治疗的晚期转移性去势抵抗性前列腺癌（mCRPC）患者中，约25%会发展为治疗相关的神经内分泌前列腺癌（NEPC）。镥-前列腺特异性膜抗原（-PSMA）是一种针对已用尽其他全身治疗方案的mCRPC患者的新兴替代疗法；然而，具有神经内分泌分化的细胞不表达PSMA，不受该治疗影响。本病例突出了骨转移对177Lu-PSMA的特殊反应，但这种反应因肝脏中的神经内分泌转化而受到影响。
Zotero 插件